Novartis

Letter to global governments: A call for bold life sciences investment

Life sciences innovation in advanced economies is under threat—not from a lack of talent, ideas, or scientific leadership, but from policy failures. The EU, Canada, Japan, and other major markets are ...
Novartis

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company ...
Novartis

Novartis announces expiration of Tourmaline Bio tender offer

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Basel, October 26, 2025 – Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based, biopharmaceutical company focused on a ...
Novartis

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
Novartis

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

Pluvicto TM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
Novartis

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with ...
Novartis

Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...
Novartis

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE ...
Novartis

New Novartis ESC data highlights strength of cardiovascular portfolio

About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...
Novartis

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...